NON-small-cell lung carcinomaHEALTH services accessibilitySOCIOECONOMIC factorsONCOGENESRacial/ethnic disparities mar NSCLC care and treatment outcomes. While socioeconomic factors and access to healthcare are important drivers of NSCLC disparities, a deeper understanding of genetic ancestry-associated genomic...
the CS1001-302 study, with an innovative design, is the first phase III clinical study in China for the first-line treatment of both squamous and non-squamous NSCLC subtypes. We will
In the past few years, we have seen emerging data from testing specific platinum doublet therapy, which is histology-appropriate for squamous or nonsquamous NSCLC, alongside various immunotherapies. I would say that the most compelling data have been from the nonsquamous population. The KEYNOTE-18...
Nonsquamous Disease Treating Squamous vs Nonsquamous DiseaseTreating Squamous vs Nonsquamous DiseaseCheryl Zigrand
This is an exciting time in squamous NSCLC where we haven't seen much progress in the past. For the patients who do not have an obvious contradiction, immunotherapy should be considered in the frontline setting as either monotherapy for a very select [group of] patients or in combination with...
Expert opinion: In the 'negative' nonsquamous NSCLC patients, first-line combinations of pembrolizumab, an anti-PD-1, or atezolizumab, an anti-PD-L1, plus chemotherapy are already available in the clinical practice, regardless of PD-L1 expression. In this group of patients, the combinations of...
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of frontline pembrolizumab (Keytruda) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer without EGFR or ALK mutations, regardless of...
(B) Non-squamous NSCLC (LAC and LCC; P ¼ 0.878; log rank); (C) early UICC stages I and II including the whole cohort (P ¼ 0.009; log rank); (D) advanced UICC stages III and IV including the whole cohort (P ¼ 0.903; log rank); (E) early UICC stages I and II in ...
In combination with chemotherapy for first-line treatment of patients with metastatic squamous and non-squamous NSCLC. For the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based c...
We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with nonsquamous NSCLC. Methods Chemotherapy-naive patients with stage IV nonsquamous NSCLC without sensitizing EGFR or ALK genetic alterations were randomiz...